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Abstract
Background:  Despite effective treatments, asthma outcomes remain suboptimal. Interest exists in
complementary therapies, particularly in herbal remedies for asthma treatment, currently with
inconclusive evidence of efficacy. The encapsulated botanical mixture AKL1 has anecdotal evidence of
effectiveness in asthma.
Methods: We performed a randomised controlled cross over study comparing the effectiveness of AKL1
with indistinguishable placebo as add-on therapy in patients uncontrolled on standard asthma treatment.
Thirty two adult asthmatics completed a 36 week trial consisting of a 4 week single blind run in period,
during which placebo was added to usual treatment, a 12 week double blind active phase in which subjects
received AKL1 or placebo, a single blind 8 week washout period receiving placebo and a final 12 week
double blind cross-over active treatment phase. Daily diaries were kept of peak expiratory flow and
symptoms, and spirometry, validated symptom and health status questionnaire scores and adverse events
were monitored at study visits. Paired T tests were used to compare the effects of placebo and AKL1 on
outcomes. Changes in outcome measures over treatment phases are presented as means and 95%
confidence intervals (CI) of means.
Results:  No significant differences in lung function (active-placebo) were found (Forced Expiratory
Volume in 1 second: mean difference [95% CI] = 0.01 [-0.12 to 0.14] L, p = 0.9. Peak Expiratory Flow: -
4.08 [-35.03 to 26.89]. L/min, p = 0.8).
Trends to clinical improvements favouring active treatment were however consistently seen in the patient-
centered outcomes: Asthma Control Questionnaire mean difference (active – placebo) [95% CI] = -0.35
[-0.78 to 0.07], p = 0.10, Asthma Quality of Life Questionnaire mean difference 0.42 [-0.08 to 0.93], p =
0.09, Leicester Cough Questionnaire mean difference 0.49, [-0.18 to 1.16], p = 0.15.
Nine exacerbations occurred during placebo treatment and five whilst on AKL1. No significant adverse
events were noted.
Conclusion:  AKL1 treatment was well tolerated. No significant improvements in lung function,
symptoms, or quality of life were seen, although consistent trends were seen to improvements in patient-
centered outcomes. Further studies are needed.
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Background
Asthma is a common chronic illness, and in spite of effec-
tive treatments outcomes remain sub-optimal [1]. Many
patients harbour misgivings about conventional medical
treatments for asthma, particularly inhaled corticosteroid
(ICS) treatment [2,3], and adherence is frequently poor
[4-6]. There is considerable public interest in complemen-
tary and alternative (CAM) treatments [7], including those
for asthma, with surveys indicating a high level of use of
all CAM treatments [8,9] but in particular of herbal treat-
ments [10,11] for asthma. There are reports that 11% [12]
to 40% [13] of people with asthma may use herbal reme-
dies, with non-disclosure to orthodox practitioners being
common.
The evidence of clinical effectiveness of herbal treatments
for asthma is inconclusive; a systematic review [10] of 17
randomised controlled trials of herbal products for the
treatment of asthma in 2000 found some promising
results, but methodological deficiencies in most of these
studies meant that uncertainly remains. Improvements in
lung function and symptoms have been reported in some
studies with different herbal agents [10]. More recent
studies have also reported similar improvements in
asthma outcomes [14-16], but the evidence for effective
herbal treatments for asthma is not yet strong enough to
make positive recommendations about specific herbal
preparations or indeed about herbal treatment in general.
AKL1 is a novel agent containing a combination of botan-
ical products developed as a treatment for asthma and for-
mulated as a capsule. The botanical product contains a
synthetically-derived phytochemical component of Picror-
rhiza kurroa, apocynin, together with Picrorrhiza kurroa,
Zingiber officinale and a standardized extract of Ginkgo
biloba. The plant materials have been standardized against
a known phytochemical marker, and additionally each
ingredient was cross evaluated by the Medicinal Chemis-
try Department at the University of Utrecht to guarantee
to standardization content as: Ginkgo biloba (standard-
ized to contain ginkgo flavone glycosides – minimum
24%), Zingiber officinale (standardized to contain gin-
gerols – minimum 5%), Picrorrhiza kurroa (enriched to
contain apocynin – minimum 30%). Each 500 mg AKL
capsule, which is a patented formulation, contains: Picror-
rhiza kurroa (enriched to contain apocynin – min 28%) –
270 mg Ginkgo biloba (standardised to contain ginkgo
flavone glycosides – min 24%) – 130 mg Zingiber offici-
nale (standardised to contain gingerols – min 5%) – 100
mg. The treatment regime is 2 capsules twice a day. The
various components of this mixture have been marked
separately as health supplements, and the mixture was
briefly sold as an over the counter health supplement
prior to withdrawal pending full clinical evaluation. The
mixture was formulated after extensive in-vitro and prag-
matic clinical experimentation.
Anecdotal clinical evidence suggests that the botanical
product has significant anti-asthma activity with patients
reporting reduced frequency of attacks, reduced use of
bronchodilators, reduced usage of inhaled corticosteroids
and reduced hospitalization rates. Patients also report
substantial reduction in cough and sputum production.
This study investigated the efficacy of this agent as 'add-
on' therapy for adult patients whose asthma remains
uncontrolled on standard medication.
Methods
This was a randomised, double-blind, placebo controlled,
cross-over study assessing the efficacy of orally adminis-
tered AKL1 capsules in addition to the normal prescribed
medication for the treatment of asthma, which continued
for the duration of the study. Consenting adults with sub-
optimally controlled asthma despite current therapy
(which included regular ICS treatment) were recruited.
The study consisted of four periods; a four week single-
blind baseline period, during which the subject continued
normal treatment and in addition took a placebo capsule,
a twelve-week double-blind treatment period during
which patients received either AKL1 or indistinguishable
placebo in addition to normal treatment, a eight week sin-
gle-blind washout period during which a placebo was
taken and a further twelve-week double-blind treatment
period during which patients crossed over from active
treatment to placebo or vice-versa. Subjects were ran-
domly assigned to receive either AKL1 or placebo in the
first and second active phase in a double-blinded manner
(Figure 1).
Subjects
Consenting adult patients aged between 18 and 75 years
with persistent asthma (defined as per GINA criteria [17])
and currently receiving inhaled corticosteroid medication
at a total daily dose of 400–2000 mcg beclomethasone
diproprionate or equivalent were recruited by advertise-
ments in local Doctor's surgeries and in the local newspa-
per. All patients had a documented positive
bronchodilator reversibility test with ≥ 15% improvement
in FEV1 from 15 to 30 minutes after inhalation of at least
200 μg of salbutamol (beta-2-adrenergic agonist adminis-
tration) or documented PEF variability of 20% as
described in BTs guidelines [18]. Exclusion criteria
included documented COPD and unstable asthma
defined the requirement for oral corticosteroids and/or
admission to hospital for asthma (including treatment in
an emergency room) in the prior three months.BMC Pulmonary Medicine 2007, 7:4 http://www.biomedcentral.com/1471-2466/7/4
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Subjects completed a daily diary of bronchodilator use
and measured Peak Expiratory Flow (PEF) rate each morn-
ing (pre-bronchodilator) and evening, utilising a PiCo
electronic PEF meter [19] with data transmitted real-time
via a mobile phone link using the eSAN electronic peak
flow meter and diary system [20]. (Due to technical prob-
lems with cell phone coverage and data transmission
problems, 8 patients elected to use paper diary cards and
a mini-Wright's peak flow meter (Clement Clarke Interna-
tional Ltd) to collect identical information). At study visits
(Table 1), spirometry was measured (Microlab), question-
naires were administered (Asthma Control Questionnaire
[21], Asthma Quality of Life Questionnaire [22], Leicester
Cough Questionnaire) [23] and blood was drawn for hae-
matological and biochemical profiles, and data was col-
lected on adverse events, asthma exacerbations and non-
study medication use.
In order to be randomised at visit 2, subjects had to use ≥
2 puff per day and ≤ 12 puffs per day of rescue medication
(salbutamol) on average during the 7 days immediately
prior to the visit, and to have experienced no exacerbation
during the lead-in period requiring additional therapy.
Study Schematic Figure 1
Study Schematic.
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Outcome measures
The primary outcome measure was the effect of AKL1 on
lung function (Peak Expiratory Flow Rate, PEF), compar-
ing for each patient the change in mean morning pre-
bronchodilator PEF between the final week of the run-in
or wash-out period and the final week of active treatment
minus the change in PEF over the same parameters for pla-
cebo treatment.
Secondary endpoints were comparisons of the changes in
individual patients over the active treatment and placebo
phases of the following parameters:
￿ Forced expiratory volume in 1 second (FEV1) measured
at study visits
￿ Asthma related health status (Juniper Asthma Quality of
Life Questionnaire scores, AQLQ)
￿ Asthma control (Juniper Asthma Control Questionnaire
scores, ACQ)
￿ Cough related health status (Leicester cough question-
naire scores, LCQ)
￿ Asthma exacerbations (defined as the need for the use of
short burst oral corticosteroid medication)
￿ Average short acting beta agonist (SABA) rescue medica-
tion use.
In addition, adverse events were recorded and the follow-
ing parameters were monitored:
￿ Blood pressure
￿ Full Blood Count
￿ Urea and Electrolytes
￿ Liver Function Tests
Sample size
Assuming that the within-patient standard deviation of
peak flow is 40 Liters/min, a study population of 30
patients will detect a treatment difference in PEF of 30 L/
min at a two-sided 5% significance level, with a power of
80%. To allowing for an estimated drop-out rate of up to
25% we therefore aimed to enroll 40 patients
Ethical approval
The study received ethical approval from the Grampian
Local Research Ethical Committee
Statistical analysis
The data were entered into an Access databases and ana-
lyzed using SPSS version 14. Paired data were analyzed
with the paired Student's T test. Descriptive demographic
statistics are presented as mean and standard deviation
(SD) for normally distributed data and median and inter-
quartlie range (IQR) for skewed data. Changes in outcome
measures over the treatment phases are presented as
means and corresponding 95% confidence intervals
(95%CIs). A p value of less than 0.05 was taken to signify
statistical significance.
Results
Patient demography
Sixty subjects were assessed at the screening visit and 43
subjects met the entry criteria and were randomised.
Eleven patients failed to complete the study; 7 withdrew
Table 1: Schedule of events
Visit No 1 2 3 4 5 6 7
Baseline Randomisation: 
Start treatment 
phase 1
Mid-Treatment 
phase 1
End of 
Treatment 
phase-Washout
Start 
Treatment 
phase 2
Mid-Treatment 
phase 2
End treatment, 
Final visit
Week No. 0 4 10 16 24 30 36
Consent X
Inclusion/exclusion criteria XX
Physical exam X X
Vital signs XX X X X X X
Blood drawn XX X
Pregnancy test XX X
Bronchodilator reversibility X
Spirometry XX X X X X X
Asthma exacerbations XX X X X X X
AQLQ XX X X X X X
ACQ XX X X X X X
LCQ XX X X X X X
Bronchodilator use XX X X X X X
Dispense study medication XX X X X X
Randomisation XBMC Pulmonary Medicine 2007, 7:4 http://www.biomedcentral.com/1471-2466/7/4
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consent and 4 became uncontactable during the study.
Thirty two patients completed the full study protocol and
provided data for analysis.
The median (IQR) age of the per-protocol population was
40.5 (33.7–55.2) yrs, and 25 subjects were female. The
mean (SD) morning pre-bronchodilator PEF during base-
line period was 386 (106) L/min, the median (IQR) FEV1
2.65 (1.93–2.95)L, median (IQR) FEV1 % predicted was
87.5 (74.2–108.7)%. The median (IQR) daily inhaled
corticosteroid dose was 800 (400–1700) mcg/day. 15
subjects received long acting beta agonists, 3 received leu-
kotriene receptor antagonists and 2 received theophyl-
lines in addition to inhaled corticosteroids and as
required short acting beta agonists. 15 subjects reported
allergies, and 7 a history of allergic rhinitis or hay fever.
The subjects' usual medical attendants were requested not
to alter maintenance asthma treatment during the study,
and no changes in asthma treatment other than short
burst changes relating to asthma exacerbations (see
below) occurred.
The mean (SD) AQLQ score at baseline were 4.76 (0.92),
ACQ score 1.83 (0.75), the median (IQR) LCQ score 5.66
(4.42–6.25), indicating sub-optimal asthma control and
moderately impaired asthma-related and cough-related
health status at baseline.
No significant differences in baseline parameters were
observed between the group randomised to receive active
treatment followed by placebo and the group randomised
to receive placebo followed by active treatment in age, sex,
current smoking status, inhaled corticosteroid dose or per-
centage predicted FEV1 (table 2).
Lung function changes
1. PEF
The individual patient changes in mean morning pre-
bronchodilator PER from the week preceding treatment
phase (i.e. the last week of run-in or of wash-out) to the
last week of active treatment phase are shown in Figure 2.
The mean difference (95% CI) in the change in mean
morning PEF for individual subjects between active treat-
ment and placebo (effect of AKL1 – effect of placebo) was
-4.1 (-35.0 to 26.9) l/min (p = 0.8), indicating no signifi-
cant change in PEF as a result of AKL1 treatment.
2. FEV1
The mean difference (95% CI) in change in FEV1 for indi-
vidual subjects between active treatment and placebo
(effect of AKL1 – effect of placebo) was 0.01 (-0.12 to
0.14) litres (p = 0.9), again indicating that AKL1 resulted
in no significant change in lung function.
Questionnaire based patient-centred outcome changes 
(Table 3)
1. Asthma heath status: AQLQ
The individual subject changes in AQLQ scores over the
active treatment and placebo phases are shown in Figure
3. The difference in change in individual subject mean
AQLQ score (effect of AKL1 – effect of placebo) showed a
trend to improvement with AKL1 treatment of 0.42 (-0.08
to 0.93), p = 0.09.
With an individual patient change in AQLQ score of 0.5
signifying a clinically relevant change in health status
[24], 42% of subject improved on AKL1, 29% of subjects
improved on placebo and 29% had similar health status
changes on AKL and placebo.
2. Asthma control: ACQ
The changes in individual subject ACQ scores over the
active treatment and placebo phases are shown in Figure
4. The difference in change in individual subject mean
ACQ score (effect of AKL1 – effect of placebo) showed a
trend to improvement with AKL treatment of -0.35 (95%
CI of the difference -0.78 to 0.07), p = 0.10.
With an individual patient change in ACQ score of 0.5 sig-
nifying a clinically relevant change in health status [24],
50% of subject improved on AKL1, 22% of subjects
improved on placebo and 28% had similar health status
changes on AKL and placebo.
3. Cough related health status (LCQ score)
The difference in change in individual subject LCQ score
(effect of AKL1 – effect of placebo) showed a trend to
improvement with AKL1 treatment of 0.49 (-0.18 to
1.16), p = 0.15.
Table 2: Baseine characteristics (age, sex, percentage predicted Forced expiratory rate in the first second (FEV1), Inhaled 
Cosirosteroid (ICS) dose in mcg/dat beclomethasone equivalent, ciuurent smoking status in groups randomsied to AKL followed by 
placebo or to placebo followed by AKL, with p values for differences between groups.
age (median, IQR) Female sex (n) FEV1 % predicted 
(median, IQR)
ICS dose, mcg/day 
(median, IQR)
Current smoker (n)
AKL1 – Placebo (n = 16) 41.00, 33.50 – 55.75 13 90.00, 79.75 – 115.50 1000, 400 – 2000 1
Placebo – AKL1 (n = 16) 35.50, 29.50 – 55.50 12 85.50, 56.50 – 110.00 800, 400 – 1150 1
P value 0.67 0.67 0.25 0.51 1.00BMC Pulmonary Medicine 2007, 7:4 http://www.biomedcentral.com/1471-2466/7/4
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Adverse outcomes
Asthma exacerbations (Table 4)
Only seven of the 32 patients in this study reported the
occurrence of exacerbations during the active treatment
phases. A total of 9 exacerbations occurred whilst taking
placebo (3 patients having a single exacerbation and 3
patients having 2 exacerbations) and a total of 5 with
AKL1 (3 patients having single exacerbation and one
patient having 2 exacerbations.
Other adverse events
Sixty non-asthma related adverse events were recorded
during the study, most related to inter-current infections
or minor illnesses; none were deemed to be treatment
related. 22 events occurred while on AKL treatment and
38 whilst on placebo (data available on request)
No significant changes in weight, pulse rate, blood pres-
sure, hematological or biochemical parameters were
found across the study period (data not presented, availa-
ble on request).
Discussion
This randomised controlled double blinded cross-over
trial compared the effects of 12 weeks of treatment with
the encapsulated botanical mixture AKL1 on lung func-
tion, asthma control, asthma and cough related health
status and on treatment related adverse outcomes with
that of 12 weeks of indistinguishable placebo capsules as
add-on treatment for patients having sub-optimally con-
trolled asthma on standard therapy at study entry.
The primary outcome of the study was lung function. No
significant or potentially relevant changes in lung func-
tion were found between active and placebo treatment. It
Change in individual subject mean morning PEF over the active treatment and placebo treatment phases (the colored lines rep- resent individual patients and the black bar the grouped mean change) Figure 2
Change in individual subject mean morning PEF over the active treatment and placebo treatment phases (the colored lines rep-
resent individual patients and the black bar the grouped mean change).
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is therefore very unlikely that AKL1 has an effect on lung
function in asthma. No statistically significant changes
secondary outcomes were found, but consistent trends
were however seen towards improvements in patient cen-
tered asthma outcomes, including symptomatic asthma
control (ACQ scores), asthma related health status
(AQLQ scores) and cough related health status (LCQ
scores). Although none of these outcome measures indi-
vidually reached statistical significance, similar trends
were seen towards improvement with AKL1 treatment
over placebo for each. It is possible that the study was
insufficiently powered to demonstrate a clinically and sta-
tistically relevant effect for these outcome measures. The
magnitude of the effect on asthma control and asthma
Table 3: Mean Changes in Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and Leicester Cough 
Questionnaire (LCQ) scores associated with AKL1 treatment (AKL1 – Placebo).
Questionnaire Mean difference (95% CI)* P-value**
ACQ -0.35 (-0.78 to 0.07 0.10
AQLQ 0.43 (-0.08 to 0.93) 0.09
LCQ 0.49 (-0.18 to 1.16) 0.14
* Negative score on ACQ indicate improved asthma control. Positive scores on AQLQ and LCQ indicate improved health status
**Students paired T Test
Change in individual subject Asthma Quality of Life Questionnaire (AQLQ) score over the active treatment and placebo treat- ment phases (the colored lines represent individual patients and the black bar the grouped mean change, higher reading  equates to improved health status) Figure 3
Change in individual subject Asthma Quality of Life Questionnaire (AQLQ) score over the active treatment and placebo treat-
ment phases (the colored lines represent individual patients and the black bar the grouped mean change, higher reading 
equates to improved health status).
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related quality of life appeared to have not been inconsid-
erable; comparing the proportions of subjects showing a
clinically relevant change in asthma control in association
with AKL1 treatment, 50% improved while 22% deterio-
rated, and for asthma-related health status, 42%
improved while 29% deteriorated. No safety concerns
emerged over AKL1 during the trial, with a numerical
decrease in asthma exacerbations and an adverse event
rate similar to placebo. The consistent trends to improve-
ment in patient centered outcomes warrant further con-
sideration and investigation
These data point to a possible dissociation between lung
function and patient centered outcomes in this study.
How are we to understand this dissociation? One possible
explanation is that as patients were recruited from the
community with mild to moderate asthma, lung function
impairment may have been too mild to demonstrate an
improvement on treatment. However, the lack of even a
trend for lung function tests effects makes it unlikely that
this fully explains this dissociation. It is well recognized
however that asthma is a complex and heterogeneous dis-
ease that affects patients in a variety of ways, and that no
single outcome measure can encompass the complexity of
asthma [25]. Poor correlations have been reported in pre-
vious studies between lung function and patient centred
outcomes such as asthma symptoms [26], and composite
outcomes encompassing a variety of measures including
patient centered parameters are increasingly used [27]. If
AKL1 is indeed having an effect on asthma, it may be that
it is affecting manifestations of the disease independent of
bronchspastic phenomena, and may result in improve-
Change in individual subject Asthma Control Questionnaire (ACQ) score over the active treatment and placebo treatment  phases (the colored lines represent individual patients and the black bar the grouped mean change, a lower score equates to  improved asthma control) Figure 4
Change in individual subject Asthma Control Questionnaire (ACQ) score over the active treatment and placebo treatment 
phases (the colored lines represent individual patients and the black bar the grouped mean change, a lower score equates to 
improved asthma control).
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ments in symptoms and hence the impact of the disease
on the individual independently of any effects on bron-
choconstriction. Further research is needed to investigate
this possibility.
The strengths of this study were that it recruited asthmat-
ics from the community (where most asthma is now
treated) with a typical demographic profile, and it used a
rigorous scientific methodology to control for the many
potential confounding factors that may bias the results of
investigations of CAM therapies. A weakness is the size of
the study; as only 32 patients completed the study, based
on a sample size calculation for a change in PEF of 30 l/
min, there were insufficient numbers to provide a statisti-
cally significant result in the secondary patient centered
outcome measures or in exacerbations. A further, larger
study is now required to investigate the effects of AKL1 on
symptom control, exacerbations and health status in
asthma. In addition, the study only investigated the use of
AKL1 as an add-on therapy, and no information can be
inferred on the use of this agent as monotherapy or as a
steroid-sparing agent.
This study recruited patient treated in the community for
mild to moderate asthma whose symptoms were not fully
controlled on standard therapy; surveys have shown that
many asthmatic patients do indeed have inadequate con-
trol [1,28,29], and that many patients are willing to put
up with inadequate control in order to limit their per-
ceived dependence on conventional preventative pharma-
cotherapy [1,29,30]. Herbal treatments are often
perceived as being more 'natural' and so more acceptable
than standard pharmacological agents, and so the demon-
stration of effectiveness for a botanical based treatment
would have the potential to offer a useful adjuvant treat-
ment to many asthmatics. The side-effect and adverse
event profile of AKL was found to be excellent in this
study.
Conclusion
This study used a cross-over randomised controlled meth-
odology to investigate whether AKL1, an encapsulated
botanical mixture, was more effective than indistinguish-
able placebo as an add-on treatment for patients whose
asthma remained uncontrolled on standard pharmaco-
therapy. No effect was observed on lung function, and no
statistically significant effects were seen in patient cen-
tered outcomes, although consistent trends were observed
to improvements in asthma symptomatic control, asthma
health status and cough health status. The tolerability pro-
file of AKL1 was excellent. Further research is required to
investigate the possibility that this treatment may be an
effective add-on treatment for asthma.
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